Skip to main content
Premium Trial:

Request an Annual Quote

Myriad to Conduct BRCA Testing for Abbott Drug Study

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market Tuesday that it will conduct BRCA testing on patients enrolled in an Abbott Laboratories drug study.

Myriad will perform BRCA1 and BRCA2 mutation testing on patients in the Phase III, multi-center study of an Abbott drug for metastatic breast cancer. The Salt Lake City-based firm said that the agreement is similar to a previous agreement for a Phase II study of the same drug.

Myriad will use its BRACAnalysis test to determine the mutation status of the patients and provide standard test reports to clinicians at each study site.

The firms did not disclose financial or other details of the agreement.